Biomedical subjects

Y-C Huang

Publications and source records attributed to Y-C Huang.

6 recordsLinked to original sources

PubMed2003

Invasive pneumococcal infections: a clinical and microbiological analysis of 53 patients in Taiwan.

OBJECTIVE: To track penicillin susceptibility among Streptococcus pneumoniae causing invasive diseases and to evaluate risk factors for antibiotic resistance. METHODS: A retrospective study was performed in a medical center of all patients with invasive pneumococcal infections based on positive microbiological findings, confirmed by appropriate clinical and laboratory findings. MICs of penicillin and ceftriaxone were determined and interpreted by NCCLS methodology. RESULTS: Fifty-three episodes of invasive S. pneumoniae infections (ISPI) among 22 children and 31 adults were identified. The disease patterns of ISPI were similar between children and adults, and the most common modes were pneumonia (70%) and primary bacteremia (23%). The rate of penicillin-nonsusceptible S. pneumoniae (PNSP) isolated from pediatric patients was higher than that in adult patients (95.5% vs. 54.8%, P < 0.001). This finding was correlated to prior antibiotic use that was more common in children (36.4%) than in adults (18.9%). The rate of penicillin-resistance among S. pneumoniae isolates (PRSP) was extremely high in this area: 45.5% from pediatric patients and 41.9% from adult patients. More adults (90.3%) with ISPI had major underlying diseases than children (4.5%). This may explain why adult patients tended to run an unfavorable outcome (mortality rate, 51.6% and 4.5% in adults and children, respectively), although most of the cases with empyema were children. None of the patients enrolled in this study received pneumococcal vaccination. CONCLUSION: We suggest that vaccines be administered for young children and the elderly with major underlying diseases to prevent ISPI.

Adolescent↗

PubMed2002

Comparison of nitric oxide production and motion characteristics after 3-layer percoll and IxaPrep preparation methods of human sperm.

OBJECTIVE: To compare two different spermatozoa preparation mediums, the three-layer Percoll (Sigma, St. Louis, MO; salica-based) and the IxaPrep (Medicult, Copenhagen, Denmark; non-salica based, polysucrose medium) method, with respect to recovery of pregressive motile sperm and various sperm motion characteristics. Analysis was determined by computer-aided sperm analysis and nitric oxide (NO) production of the supernatant after centrifugation. METHOD: Thirty-nine semen specimens were obtained from men who presented for semen analysis and each of them was divided into two aliquots for preparation with the two mediums mentioned above. The motile sperm recovery, motility percentage and motion parameters were measured for each semen specimen (n=39) before and after preparation using one of the two above methods. The NO was measured using the chemiluminscence method after centrifugation. RESULTS: Recovery rate was higher in the IxaPrep group (Ixaprep: 45.4+/-28.7% versus Percoll: 32.3+/-22.7%; p<0.05). The other motion characteristics such as average path velocity (VAP) and straight line velocity (VSL) were better than those of fresh semen samples [VAP: 72+/-17.2 micro m/s (Percoll), 62.8+/-18.2 micro m/s (Ixaprep) vs 52.2+/-9.5 micro m/s (fresh); p<0.05; VSL: 51.8+/-13.4 micro m/s (Percoll), 44.8+/-12.9 micro m/s (Ixaprep) vs 38.6+/-7.9 micro m/s (fresh); p<0.05]. The motility between fresh and post-preparation semen samples had no significant difference. Hyperactivation of the sperm was improved in the IxaPrep group compared with fresh sperm (Percoll: 24.7+/-16.9% and IxaPrep: 20.5+/-10.5% versus fresh: 9.2+/-9.2%; p<0.05). NO produced in the IxaPrep method was significantly lower than that in the Percoll method (Ixaprep: 0.24+/-0.3 micro M versus Percoll: 0.54+/-0.91 micro M; p<0.05). CONCLUSION: Our data suggests that the IxaPrep method provides a better recovery rate, but that other motion characteristics did not demonstrate any significant difference. The lower level of NO produced in the IxaPrep preparation method may suggest that better sperm quality achieved is due to the decreased NO production.

Cell Separation↗

PubMed2002

Vitamin B6 intakes and status of mechanically ventilated critically ill patients in Taiwan.

OBJECTIVE: To assess vitamin B6 intake and status of critically ill patients. The relationship between vitamin B6 status indicators and the severity of illness and outcome in these patients was also examined. DESIGN: Prospective clinical study. SETTING: The study was performed at the Taichung Veteran General Hospital, in the central part of Taiwan. SUBJECTS: Ninety-four patients in the intensive care unit (ICU) entered the study and 46 patients successfully completed this study. INTERVENTIONS: No intervention. MAIN OUTCOME MEASURES: Vitamin B6 intake was recorded for 14 days. Vitamin B6 status was assessed by direct measures (plasma pyridoxal 5'-phosphate (PLP), pyridoxal (PL), and urinary 4-pyridoxic acid (4-PA)) and indirect measures (erythrocyte alanine (EALT-AC) and aspartate (EAST-AC) aminotransaminase activity coefficient). The severity of illness (APACHE II score), the length of ventilation dependency, and the length of ICU and hospital stay were recorded. RESULTS: Patients had an adequate mean vitamin B6 intake (16.26+/-19.39 mg) during the 14 day study. Mean vitamin B6 intake was significantly higher on day 14 than on day 1 (P<0.001). However, plasma PLP and PL concentrations significantly decreased at the 14th day after admission (P<0.05). Erythrocyte alanine aminotransaminase activity coefficient and EAST-AC did not change significantly. Urinary 4-PA significantly increased at the 14th day (P<0.001). No significant relationships were found between APACHE II scores and clinical outcomes (the length of ICU and hospital stay, the length of ventilation dependency) of patients, vitamin B6 intake or status indicators. CONCLUSIONS: Critically ill patients received nutritional support in the ICU, and had sufficient mean vitamin B6 intake and adequate vitamin B6 status. Therefore, the severity of illness and the results should not be affected by vitamin B6 status. However, we have noted that plasma PLP and PL concentrations significantly decreased while vitamin B6 intake significantly increased on day 14. Critical clinical conditions and complex metabolism in the critically ill may account for the reduction of plasma PLP and PL. Since vitamin B6 deficiency causes profound effects on immune system function, dietary or supplemented vitamin B6 intake is suggested for hospitalized patients.

APACHE↗

PubMed2002

Measured versus estimated energy expenditure in mechanically ventilated critically ill patients.

Accurate determination of energy expenditure is essential in patients receiving nutritional support to meet metabolic needs. The purpose of this study was to assess and compare the energy expenditure as measured by indirect calorimetry (MEE) and estimated by 5 equations in the mechanically ventilated critically ill patients. Forty-six patients were divided into either enteral nutrition (EN) (n=l2), total parenteral nutrition (TPN) (n=16) or combined (EN plus TPN) (n=l8) groups. Patients' energy expenditure was measured by indirect calorimetry on two occasions. Anthropometric and biochemical measurements, energy expenditure and medical status (APACHE II score) were also assessed in the intensive care unit (ICU) of Taichung Veteran General hospital. No significant difference was found in the MEE among the 3 groups. The type of nutritional support did not affect MEE. Energy expenditure calculated by using Harris- Benedict, Kleiber and Liu equations times the estimated stress factor did not significantly different than the values of MEE in all groups. There were significant correlations (P<0.01) between MEE and patients' sex (r=-0.499), age (r=-0.402), height (r=0.533), knee height (r=0.431), current body weight (r=0.379), usual body weight (r=0.407), ideal body weight (r=0.466) and urinary urea nitrogen (r=0.383) in the pooled group. Results demonstrated that energy expenditure could be estimated in most critically ill patients by using Harris-Benedict, Kleiber and Liu equations if the estimated stress factor is in the reasonable value.

Aged↗

PubMedDate not supplied

The characteristics of betamethasone-loaded chitosan microparticles by spray-drying method.

Betamethasone (BTM)-loaded microparticles prepared by a spray drying method using chitosan (CTS) as raw material, type-A gelatin and ethylene oxide-propylene oxide block copolymer (Pluronic F68) as modifiers. The BTM-loaded in varied chitosan/Pluronic F68/gelatin microparticle formulations was investigated. By properly choosing excipient type and concentration a high degree of control was achieved over the physical properties of the BTM-loaded microparticles. Microparticle characteristics (zeta potential, tap density, particle size and yield), loading efficiencies, microparticle morphology and in-vitro release properties were examined. Surface morphological characteristics and surface charges of prepared microparticles were observed by using scanning electron microscopy (SEM) and microelectrophoresis. A SEM micrograph shows that the particle sizes of the varied chitosan composed microparticles ranged from 1.1-4.7 microm and the external surfaces appear smooth. The BTM-loaded microparticles entrapped in the chitosan/Pluronic F68/gelatin microparticles with trapping efficiencies up to 93%, collected yield rate 44%, and mean particle size varied between 1-3 microm, positive surface charge (20-40 mv), and tap densities (0.04-0.40 g/cm3) were obtained. The collected BTM yield and size of particle was increased with increasing BTM-loaded amount but both zeta potential and tap density of the particles decreased with increasing BTM-loaded amount. The in vitro release of BTM showed a dose-dependent burst followed by a slower release phase that was proportional to the drug concentration in the concentration range between 5-30%w/w. The in vitro drug release from the chitosan/Pluronic F68/gelatin 1/0.1/0.4 microspheres had a prolong release pattern. These formulation factors were correlated to particulate characteristics for optimizing BTM microspheres in pulmonary delivery.

Anti-Inflammatory Agents↗

PubMedDate not supplied

Optimizing formulation factors in preparing chitosan microparticles by spray-drying method.

The chitosan only, chitosan/Pluronic F68, chitosan/gelatin, chitosan/Pluronic F68/gelatin microparticles and betamethasone-loaded chitosan/Pluronic F68/gelatin microparticles were successfully prepared by a spray-drying method. Microparticle characteristics (yield rate, zeta potential, particle size and tap density), loading efficiencies, microparticle morphology and in-vitro release properties were investigated. By properly choosing excipient type, concentration and varying the spray-drying parameters, a high degree of control was achieved over the physical properties of the dry chitosan powders. SEM micrograph shows that the particle sizes of the varied chitosan composed microparticles ranged from 2.12-5.67 microm and the external surfaces appear smooth. Using betamethasone as model drug, the spray-drying is a promising way to produce good spherical and smooth surface microparticles with a narrow particle size range for controlled delivery of betamethasone. The positively charged betamethasone-loaded microparticles entrapped in the chitosan/Pluronic F68/gelatin microparticles with trapping efficiencies up to 94.5%, yield rate 42.5% and mean particle size 5.64 microm varied between 4.32-6.20 microm and tap densities 0.128 g/cm(3). The pH of particle was increased with increasing betamethasone-loaded amount, but both zeta potential and tap density of the particles decreased with increasing betamethasone-loaded amount. The betamethasone release rates from chitosan/Pluronic F68/gelatin microparticles were influenced by the drug/polymer ratio in the manner that an increase in the release% and burst release% was observed when the drug loading was decreased. The in vitro release of betamethasone showed a dose-dependent burst followed by a slower release phase that was proportional to the drug concentration in the concentration range between 14-44%w/w.

Betamethasone↗